News
- Author:
- Sue Hughes
Publish date: October 27, 2020
“Standard prophylaxis as recommended in the guidelines is a low dose of low-molecular-weight Read More
News
- Author:
- Sue Hughes
Publish date: October 6, 2020
MS does not appear to be associated with higher risks of severe COVID-19 outcomes compared with the general population.
News
- Author:
- Sue Hughes
Publish date: September 25, 2020
Adverse effects – particularly frequency of infection – were increased in the high-dose group.
News
- Author:
- Sue Hughes
Publish date: September 24, 2020
Rare but serious and possibly life-threatening autoimmune events that have recently been linked to the drug.
News
- Author:
- Sue Hughes
Publish date: September 24, 2020
A higher percentage of total B cells, and in particular plasmablasts, could be a very predictive biomarker for autoimmunity after alemtuzumab treat...
News
- Author:
- Sue Hughes
Publish date: September 14, 2020
The investigational drug has shown a positive result in slowing disability in patients with primary progressive and secondary progressive forms of ...
News
- Author:
- Sue Hughes
Publish date: September 14, 2020
“There is now no doubt that there is an MS prodrome measurable by increased healthcare usage and lifestyle changes that are recognizable 5-10 years...
News
- Author:
- Sue Hughes
Publish date: September 12, 2020
Even low levels of exposure to cardiovascular risk factors are important in MS and might affect brain atrophy—and therefore long-term disability—ev...
News
- Author:
- Sue Hughes
Publish date: September 2, 2020
The BRACE CORONA study found no difference in key outcomes between patients continuing versus stopping their medication.
News
- Author:
- Sue Hughes
Publish date: August 31, 2020
The PCSK9 inhibitor lowered LDL cholesterol by 38% vs placebo in HAUSER-RCT, the first randomized controlled trial of one of these agents in the pe...
News
- Author:
- Sue Hughes
Publish date: August 30, 2020
Aspirin alone after TAVI significantly reduced bleeding compared with aspirin plus clopidogrel, without increasing thromboembolic events, in the la...
News
- Author:
- Sue Hughes
Publish date: August 21, 2020
Learning disorders should be taken into account when advising on recovery times and return to sport.
News
- Author:
- Sue Hughes
Publish date: August 7, 2020
An update of the Lancet Commission on Dementia Prevention, Intervention, and Care adds three new modifiable risk factors.
News
- Author:
- Sue Hughes
Publish date: August 4, 2020
The agency approved the drug for patients 1 year of age and older.
News
- Author:
- Sue Hughes
Publish date: August 3, 2020
Atogepant 10, 30, and 60 mg, were associated with a significant reduction from baseline in mean monthly migraine days compared with placebo.
